KDR and pulmonary arterial hypertension: Combined use of the vascular endothelial growth factor receptor (VEGFR) inhibitor SU5416 and exposure to hypoxia (SUHx) in rats leads to severe PAH and closely mimics the vascular changes seen in patients with severe PAH [13], [14], [15].